Alkermes (ALKS) Recently Broke Out Above the 50-Day Moving Average
Alkermes (ALKS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ALKS broke through the 50-day moving average, which suggests a sh...
Alkermes (ALKS) Grants Teva License to Market Generic Drug
Alkermes (ALKS) grants Teva an exclusive license to market a generic version of Vivitrol in the United States, thereby resolving patent litigation. The stock of the company rises 7%.
Alkermes shares surge after settlement with Teva on alcohol dependence treatment
Shares of Alkermes PLC ALKS, +9.68% jumped 10% Wednesday after the Dublin-based biopharma company announced a settlement of patent litigation with Teva Pharmaceuticals USA Inc. TEVA, relating to Vi...
Lybalvi: Weighing In Light, But Tipping Alkermes' Scales
Alkermes to split neuroscience and oncology divisions; strong growth with drug Lybalvi highlighted. Financials show robust growth; concerns include a projected 2024 revenue dip and Vivitrol litigat...
Related Companies